The Goldman Sachs Group Initiates Coverage on Merus (NASDAQ:MRUS)

Stock analysts at The Goldman Sachs Group initiated coverage on shares of Merus (NASDAQ:MRUS - Get Free Report) in a research report issued to clients and investors on Thursday,Briefing.com Automated Import reports. The brokerage set a "buy" rating and a $73.00 price target on the biotechnology company's stock. The Goldman Sachs Group's price objective would indicate a potential upside of 70.04% from the company's current price.

A number of other analysts have also recently weighed in on MRUS. Needham & Company LLC reiterated a "buy" rating and set a $85.00 price target on shares of Merus in a research note on Wednesday. Canaccord Genuity Group restated a "buy" rating and set a $67.00 target price on shares of Merus in a report on Thursday, July 25th. UBS Group initiated coverage on shares of Merus in a research note on Thursday, October 24th. They set a "buy" rating and a $72.00 price objective for the company. Guggenheim boosted their price target on Merus from $93.00 to $111.00 and gave the stock a "buy" rating in a report on Tuesday, October 1st. Finally, Canaccord Genuity Group raised shares of Merus to a "strong-buy" rating in a research note on Thursday, July 25th. One research analyst has rated the stock with a sell rating, twelve have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus price target of $85.45.

Merus Trading Down 1.3 %

Shares of Merus stock opened at $42.93 on Thursday. The company has a fifty day simple moving average of $50.72 and a 200-day simple moving average of $51.92. Merus has a 12-month low of $22.26 and a 12-month high of $61.61. The stock has a market cap of $2.94 billion, a price-to-earnings ratio of -10.87 and a beta of 1.12.

Merus (NASDAQ:MRUS - Get Free Report) last issued its quarterly earnings data on Thursday, October 31st. The biotechnology company reported ($0.95) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.90) by ($0.05). The firm had revenue of $11.77 million for the quarter, compared to analysts' expectations of $9.11 million. Merus had a negative return on equity of 38.89% and a negative net margin of 680.61%. On average, analysts forecast that Merus will post -3.89 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Merus

A number of institutional investors have recently added to or reduced their stakes in the company. FMR LLC grew its holdings in shares of Merus by 10.4% during the 3rd quarter. FMR LLC now owns 6,873,926 shares of the biotechnology company's stock worth $343,421,000 after purchasing an additional 648,994 shares during the period. Wellington Management Group LLP grew its stake in Merus by 73.6% during the third quarter. Wellington Management Group LLP now owns 2,887,514 shares of the biotechnology company's stock worth $144,260,000 after buying an additional 1,224,573 shares during the period. Deerfield Management Company L.P. Series C increased its position in shares of Merus by 3.8% in the second quarter. Deerfield Management Company L.P. Series C now owns 2,749,401 shares of the biotechnology company's stock worth $162,682,000 after acquiring an additional 100,000 shares in the last quarter. Federated Hermes Inc. raised its stake in shares of Merus by 6.7% in the 2nd quarter. Federated Hermes Inc. now owns 2,398,800 shares of the biotechnology company's stock valued at $141,937,000 after acquiring an additional 150,000 shares during the period. Finally, Samlyn Capital LLC raised its stake in shares of Merus by 11.9% in the 2nd quarter. Samlyn Capital LLC now owns 2,324,195 shares of the biotechnology company's stock valued at $137,523,000 after acquiring an additional 247,605 shares during the period. Hedge funds and other institutional investors own 96.14% of the company's stock.

About Merus

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.